WASHINGTON – Closely guarded briefing documents released by the FDA Friday morning revealed more details about the ongoing internal debate at the agency about whether GlaxoSmithKline plc's Type II diabetes drug Avandia (rosiglitazone) should be removed from the U.S. market. (BioWorld Today) Read More
